IL195360A - Prodrug of phenolic opioids, a method of preparing them, a drug that includes them and their use - Google Patents

Prodrug of phenolic opioids, a method of preparing them, a drug that includes them and their use

Info

Publication number
IL195360A
IL195360A IL195360A IL19536008A IL195360A IL 195360 A IL195360 A IL 195360A IL 195360 A IL195360 A IL 195360A IL 19536008 A IL19536008 A IL 19536008A IL 195360 A IL195360 A IL 195360A
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
phenolic opioid
opioid prodrugs
prodrugs
Prior art date
Application number
IL195360A
Other languages
English (en)
Hebrew (he)
Other versions
IL195360A0 (en
Original Assignee
Signature Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature Therapeutics Inc filed Critical Signature Therapeutics Inc
Publication of IL195360A0 publication Critical patent/IL195360A0/en
Publication of IL195360A publication Critical patent/IL195360A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL195360A 2006-05-26 2008-11-18 Prodrug of phenolic opioids, a method of preparing them, a drug that includes them and their use IL195360A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80908206P 2006-05-26 2006-05-26
US90179507P 2007-02-16 2007-02-16
PCT/US2007/069683 WO2007140272A2 (en) 2006-05-26 2007-05-24 Controlled release of phenolic opioids

Publications (2)

Publication Number Publication Date
IL195360A0 IL195360A0 (en) 2009-08-03
IL195360A true IL195360A (en) 2015-05-31

Family

ID=38645732

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195360A IL195360A (en) 2006-05-26 2008-11-18 Prodrug of phenolic opioids, a method of preparing them, a drug that includes them and their use

Country Status (14)

Country Link
US (3) US8217005B2 (OSRAM)
EP (2) EP2046393B1 (OSRAM)
JP (3) JP5371746B2 (OSRAM)
KR (1) KR20090031519A (OSRAM)
AU (1) AU2007267510B2 (OSRAM)
BR (1) BRPI0712819B8 (OSRAM)
CA (1) CA2653741C (OSRAM)
DK (1) DK2046393T3 (OSRAM)
ES (1) ES2456674T3 (OSRAM)
IL (1) IL195360A (OSRAM)
MX (1) MX2008014794A (OSRAM)
RU (1) RU2469038C2 (OSRAM)
SG (1) SG172633A1 (OSRAM)
WO (1) WO2007140272A2 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2046393T3 (da) * 2006-05-26 2014-05-12 Signature Therapeutics Inc Kontrolleret frigivelse af phenol-opioider
WO2008101202A1 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
WO2009092071A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
US20110237614A1 (en) * 2008-09-16 2011-09-29 Nektar Therapeutics Pegylated Opioids with Low Potential for Abuse
CN102186467B (zh) 2008-10-17 2014-06-04 特色疗法股份有限公司 具有减弱释放酚类阿片样物质的药用组合物
US20100227921A1 (en) * 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
AU2010231126A1 (en) * 2009-04-02 2011-10-13 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
WO2011008636A1 (en) * 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives
EP2475429B1 (en) 2009-09-08 2015-07-29 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2560489A4 (en) * 2010-04-21 2014-01-22 Signature Therapeutics Inc COMPOSITIONS WITH ENZYMSPALTBAR OPIOID PRODRUGS AND HEMMER FOR THIS
US20110262359A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US9238020B2 (en) * 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
WO2011133151A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof
CN103384472B (zh) 2011-01-11 2016-01-20 特色疗法股份有限公司 包含酶可裂解的羟考酮药物前体的组合物
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
AU2012225337B2 (en) 2011-03-09 2016-04-28 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
CN102920995B (zh) * 2011-08-10 2015-08-26 辽宁药联制药有限公司 一种治疗肝损伤的药物组合物
WO2013093931A2 (en) 2011-09-19 2013-06-27 Sun Pharma Advanced Research Company Ltd. Novel prodrugs of phenolic drugs
JP5977355B2 (ja) 2011-09-29 2016-08-24 エコール ノルマル シュペリウール ドゥ リヨン ペプチダーゼの蛍光発生基質
JP5769889B2 (ja) 2011-10-26 2015-08-26 ケムファーム・インコーポレーテッド ヒドロモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、そのプロドラッグ、製造法及び使用
JP6270547B2 (ja) * 2014-03-04 2018-01-31 公益財団法人微生物化学研究会 新規生物活性物質
GB2545368B (en) 2014-10-20 2021-04-21 Elysium Therapeutics Inc Diversion-resistant opioid formulations
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
NZ731591A (en) 2014-11-25 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
NZ731586A (en) 2014-12-02 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
CA3025268A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US20200207782A1 (en) * 2017-09-22 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd Chemically activated water-soluble prodrug
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
US12384744B2 (en) 2021-09-29 2025-08-12 Ensysce Biosciences Inc. Enzyme-cleavable methadone prodrugs and methods of use thereof
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3927036A (en) * 1972-05-25 1975-12-16 Abbott Lab Basic carbonates and carbamates of benzopyrans
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
ATE186222T1 (de) 1995-03-14 1999-11-15 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
ES2177771T3 (es) 1995-03-14 2002-12-16 Siemens Ag Dispositivo atomizador ultrasonico con unidad desmontable de dosificacion de precision.
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
JP2002540073A (ja) * 1999-03-10 2002-11-26 ロータス バイオケミカル コーポレイション 化学化合物の保護および放出のためのタンパク質コンホメーションの使用
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
AU2002351388A1 (en) 2001-12-14 2003-06-30 The University Of Wyoming Methods and compositions for controlled release of drugs
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
CA2477004C (en) 2002-02-22 2011-05-10 Thomas Piccariello Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20040086551A1 (en) 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
EP1594513B1 (en) * 2003-01-13 2011-08-10 Shire LLC Carbohydrate conjugates to prevent abuse of controlled substances
EP1603597B1 (en) * 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
US8524272B2 (en) 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
AU2004277400B2 (en) * 2003-09-30 2009-01-22 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
EP1928881A2 (en) * 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
DK2046393T3 (da) 2006-05-26 2014-05-12 Signature Therapeutics Inc Kontrolleret frigivelse af phenol-opioider
US20080207668A1 (en) 2006-10-06 2008-08-28 New River Pharmaceuticals Inc. Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
WO2008157627A1 (en) 2007-06-21 2008-12-24 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
US20090076141A1 (en) 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain

Also Published As

Publication number Publication date
BRPI0712819B8 (pt) 2021-05-25
CA2653741C (en) 2015-07-07
BRPI0712819A2 (pt) 2013-03-26
US8921418B2 (en) 2014-12-30
US20150148284A1 (en) 2015-05-28
HK1127901A1 (en) 2009-10-09
JP2009538348A (ja) 2009-11-05
MX2008014794A (es) 2009-04-08
EP2402037B8 (en) 2019-12-04
AU2007267510A1 (en) 2007-12-06
BRPI0712819B1 (pt) 2021-04-06
JP2015096554A (ja) 2015-05-21
WO2007140272A2 (en) 2007-12-06
ES2456674T3 (es) 2014-04-23
RU2469038C2 (ru) 2012-12-10
KR20090031519A (ko) 2009-03-26
AU2007267510B2 (en) 2013-01-31
EP2402037B1 (en) 2019-10-23
SG172633A1 (en) 2011-07-28
EP2402037A1 (en) 2012-01-04
US20100035826A1 (en) 2010-02-11
US20120270894A1 (en) 2012-10-25
EP2046393A2 (en) 2009-04-15
WO2007140272A3 (en) 2008-02-14
JP2013224329A (ja) 2013-10-31
EP2046393B1 (en) 2014-02-12
JP5371746B2 (ja) 2013-12-18
RU2008151690A (ru) 2010-07-10
IL195360A0 (en) 2009-08-03
DK2046393T3 (da) 2014-05-12
CA2653741A1 (en) 2007-12-06
US8217005B2 (en) 2012-07-10

Similar Documents

Publication Publication Date Title
IL195360A (en) Prodrug of phenolic opioids, a method of preparing them, a drug that includes them and their use
IL193340A0 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL202892A (en) Diphthoid drugs, the process of making and using them to make the resulting drugs and drugs
SI2101740T1 (sl) Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode
ZA200704957B (en) Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
IL225637A0 (en) The compositions, tablets containing such compositions, their use and a process for their preparation
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
IL198301A (en) Aryl amides are stored in thiazole and oxazole, a pharmaceutical preparation containing them and their use in the preparation of drugs
IL220800A (en) Stabilized Pharmaceutical Preparations Containing Passoterodine
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
PL2002828T3 (pl) Stały preparat farmaceutyczny
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
ZA200806399B (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
IL199254A (en) Derivatives of Aminoguanidine, Pharmaceuticals Containing Them, Process of Preparing and Using Them
ZA200704955B (en) Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200704956B (en) Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
HUP0600097A3 (en) Pharmaceutical compositions comprising tacrolimus and process for their preparation
IL200952A0 (en) Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed